New project will develop cancer maps for Pennsylvania

December 15, 2003

A three-year, $736,000 grant from the Association of American Medical Colleges and Centers for Disease Control and Prevention (CDC) will allow Penn State Cancer Institute to develop cancer maps to identify Pennsylvania communities with particularly high rates of colorectal and prostate cancer.

"A picture, or a map in this case, is worth a thousand words," said Eugene Lengerich, V.M.D., M.S., principal investigator for the grant and associate professor of health evaluation sciences, Penn State College of Medicine. "Our goal is to use the latest mapping technology to bolster the ongoing efforts of Pennsylvania communities to prevent cancer. Our communities deserve the latest technology."

Armed with information about cancer rates in specific geographic areas, individuals, organizations, health care providers and government agencies can better plan and evaluate cancer interventions in Pennsylvania communities.

The model developed under this grant will be based on prostate and colorectal cancers because available screenings and interventions provide significant opportunity to reduce the burden of these cancers. Once developed, this model can be expanded not only to other cancer types, but also to other states.

Based on data from the Pennsylvania Central Cancer Registry of the state Department of Health, the extent of the burden of colorectal and prostate cancers varies by geographic region. For example, the rate of colorectal cancer death in individual counties in 2000 varied from 28.8 per 100,000 to 15.8 per 100,000, and the rates of prostate cancer varied even more greatly.

Researchers have used statistics and maps to better understand reasons for the great variation in cancer burden.

"The common tools available to do this, which include paper atlases, are somewhat effective, but they are not interactive and cannot be tailored to yield data about individual communities," Lengerich said. "There is a substantial gap between the current and the best methods to visually and statistically analyze and interpret geographic variation in cancer burden. This project will produce accurate, timely, and innovative display and analysis of geographically-based cancer data."

The grant pulls together epidemiologists, geographers and communications experts at Penn State Cancer Institute and Penn State University to use complex epidemiology, statistics and learning theory to ensure the new database will provide maps that are both highly accurate, and understandable.

"This is another example of how the resources of Penn State Cancer Institute and the expertise of our physicians and researchers are improving care and treatment for those at risk for and fighting cancer," said Thomas Loughran, M.D., director, Penn State Cancer Institute at Penn State Hershey Medical Center. "The work being done by Dr Lengerich and his colleagues will lead to a greater understanding of how we can better help our Pennsylvania communities."

Lengerich's co-investigators are Gary Chase, Ph.D., Department of Health Evaluation Sciences and Penn State Cancer Institute at Penn State Milton S. Hershey Medical Center, Alan MacEachren, Ph.D., and David O'Sullivan, Ph.D., Department of Geography and GeoVISTA Center, and Roxanne Parrott, Ph.D., Department of Communications Arts and Sciences, Penn State University.

"We are working closely with an advisory committee which includes representatives from the CDC, National Cancer Institute, and the North American Association of Central Cancer Registries, to be sure that our system will be useful to many state health agencies in their cancer prevention and treatment efforts," Lengerich said.
Penn State Cancer Institute is a partnership of institutions dedicated to enhancing cancer services throughout central Pennsylvania. Through this partnership, the benefits of cancer research and education at Penn State College of Medicine reach not only patients at Penn State Hershey Medical Center, but also at the Institute's other members; the Lehigh Valley Hospital and Health Network in Allentown and Centre Community Hospital in State College. Services are also provided at Lewistown Hospital, a Cancer Institute associate member. Each year, more than 4,300 new cancer patients seek treatment at one of the Cancer Institute's partner facilities.

Penn State

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to